Inhibit Coatings is tackling one of the leading causes of preventable deaths globally – Hospital Acquired Infections.  In the US it’s estimated that the direct costs of treating these infections are ~$45 B per annum. With over 60% of these infections relating to indwelling medical devices, antimicrobial medical devices have the potential to save thousands of lives and billions of dollars.

Inhibit has developed and patented low cost antimicrobial medical grade polyurethanes that are a drop-in replacement for existing medical plastics. The value proposition has been validated with world leading clinicians and medical device manufacturers. Inhibit is now scaling to meet commercial manufacturing volumes and complete FDA safety testing.develops and produces the world’s best antimicrobial coatings with the highest performance that lasts the lifetime of the coating. It helps food producers and healthcare providers save money, protect their brands – and save lives.

Enterprise Angels first invested in Inhibit Coatings in 2019 and it is part of the EA Fund 3 portfolio.